CA
NZ
UK
AU
IND
US
• Praxis Precision Medicines (NASDAQ: PRAX) received a three-month extension for its relutrigine New Drug Application review, with the new FDA target action date set for late December.
• Rani Therapeutics (NASDAQ: RANI) appoints Nicholas Maestas as Chief Financial Officer, effective June 29, 2026.
• Aimei Health Technology director Julianne Huh resigned effective June 24, 2026, citing personal reasons.
• SS Innovations International Inc. Has been recognized as the Outstanding Company at the 2026 Surgical Robotics Industry Awards.
• Protara Therapeutics (NASDAQ: TARA) confirmed the resignation of Chief Medical Officer Leonardo Viana Nicacio, effective June 26, 2026.
• Neurogene Inc. (NASDAQ: NGNE) filed recent clinical findings from its early-stage trial of NGN-401 for Rett syndrome as Exhibit 99.1.
• NovoCure (NASDAQ: NVCR) announced Optune Pax received a CE Mark for treating pancreatic cancer in adults.
• Oncotelic Therapeutics (OTC: OTLC) secured a $178,410 convertible note from Pacific Pier Capital II, LP, with a one-year maturity.
• The company is working with regulators to refine its submission approach for the VIASkin Peanut Patch.
• The deal includes milestone-based warrants potentially unlocking up to $17.5 million in additional funding.
Please wait processing your request...